Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Terumo pursues treatments for diabetes and complications

Sep. 6, 1996

Retinoid compound from Sparta enters U.S. clinical trials

Sep. 6, 1996

A new CETP inhibitor from Schering-Plough

Sep. 6, 1996

Japanese researchers describe natural lipid-lowering agents

Sep. 6, 1996

New agents for bone disorders from Banyu

Sep. 6, 1996

GRF(1-44) research alliance

Aug. 30, 1996

Merck & Co. reports on L-163689

Aug. 30, 1996

Aldose reductase/5-lipoxygenase inhibitors reported by Tsumura

Aug. 30, 1996

Aldose reductase inhibitors from Terumo

Aug. 30, 1996

Sankyo reports novel hypoglycemic agents

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...